Literature DB >> 20418030

EMAS position statement: managing the menopause in women with epilepsy.

C Tamer Erel1, Marc Brincat, Marco Gambacciani, Irene Lambrinoudaki, Mette H Moen, Karin Schenck-Gustafsson, Florence Tremollieres, Svetlana Vujovic, Serge Rozenberg, Margaret Rees.   

Abstract

INTRODUCTION: Epilepsy is a major public health problem worldwide which is clinically characterized by recurrent seizures. AIM: The aim of this position statement is to provide evidence-based advice on management of the menopause in postmenopausal women derived from the limited data available.
MATERIALS AND METHODS: Literature review and consensus of expert opinion. RESULTS AND
CONCLUSIONS: Women with epilepsy may undergo an earlier natural menopause, between 3 and 5 years depending on seizure frequency, but the data are limited. Data regarding the effects of the perimenopause and menopause on epilepsy are conflicting: some studies show an increased risk of seizures but others do not. With regard to hormone therapy (HT) one study has shown an increase in seizures with oral therapy with conjugated equine estrogens and medroxyprogesterone acetate, but no data are available for other regimens. Women starting HT should be closely monitored as their antiepileptic drug (AED) needs may change. As vitamin D and calcium metabolism can be affected by AEDS, supplements should be considered. Herbal preparations should be avoided as their efficacy is uncertain and they may interact with AEDs. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20418030     DOI: 10.1016/j.maturitas.2010.03.026

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  1 in total

1.  Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.

Authors:  Riley Bove; Brian C Healy; Alexander Musallam; Bonnie I Glanz; Philip L De Jager; Tanuja Chitnis
Journal:  Mult Scler       Date:  2015-10-07       Impact factor: 6.312

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.